Insulet (NSDQ:PODD) touted data today from the 1st feasibility study of its Omnipod Horizon hybrid closed-loop system in patients with Type 1 diabetes. Data from the study showed that the Omnipod automated glucose control algorithm performed well, with minimal hypoglycemia, and that it was safe.
The Billerica, Mass.-based company enrolled 24 patients with Type 1 diabetes in the 36-hour study. The feasibility trial used a modified version of Insulet’s Omnipod, a Dexcom continuous glucose monitor and Insulet’s personalized model predictive control algorithm.
Get the full story at our sister site, Drug Delivery Business News.